Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012

–Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function –Comparability to ERT Also Demonstrated in Important Fabry Disease Biomarker, Plasma Lyso-Gb3 –Proceeding with Centralized Procedure for European MAA Submission August 20th, 2014 Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced …